LittleDabbie
- Posts
- 11,813
- Reactions
- 20,319
- Joined
- Mar 9, 2014
- Points
- 438
An extract of cannabis called cannabidiol, or CBD, is being studied as a potential drug to prevent or treat psychosis and also serves to clarify the marijuana-psychosis link. Research has reportedly shown that CBD counteracts the psychotic effects of THC, or delta-9-tetrahydrocannabinol, which is responsible for the drug's so-called "high" and triggers psychosis.
Results of another study led by researchers at King's College London, which gave rise to the marijuana psychosis link, suggest that skunk users triple their risk of psychosis compared with non-users, and even quintuple it if used daily. According to Amir Englund, one of the proponents of the study, the proportions of THC and CBD are about equal, at 4 percent each, in traditional hash. But in skunk, THC reaches around 14 to 15 percent while there is barely a trace of CBC.
CBD has even shown to be effective as an antipsychotic medicine.
A study in Germany, published in 2013, reportedly found that CBD alleviated psychotic symptoms in 33 patients with schizophrenia without the usual side effects, such as movement disturbances, weight gain and sexual dysfunction. It was shown that in 48 healthy volunteers, 42 percent had psychotic episodes following injections of THC while the number went down to 14 percent when they took a tablet of CBD beforehand. Also, users of CBD were found less likely to suffer paranoid episodes and memory loss onword-recall tests.
Purified cannabidiol was tested by GW Pharmaceuticals in Cambridge, UK as a possible treatment for psychosis in 80 individuals with schizophrenia to see if it reduces their risk of psychosis. Researchers reportedly found that psychosis was three times more likely in those who smoked high-potency skunk compared to non-users.
Robin Murray, who co-led the team at King's College, noted that the risk was fivefold among daily users of skunk. People who smoked low-potency hash were also found to be no more likely to experience psychosis than non-users.
Dr. Marta Di Forti, the lead author of the study, noted that the risk of psychosis in cannabis depends on both the frequency of use and potency. However, the team reportedly discovered that milder variants of cannabis, like hashish, did not increase the risk of psychotic illness.
David Nutt of the Imperial College London, who is for the decriminalization of cannabis, believes that if consumption of cannabis is made legal, the negative effects of the marijuana-psychosis link would be minimized, because skunk would disappear.
http://www.ischoolguide.com/article...ulprit-another-extract-cbd-counters-study.htm
Results of another study led by researchers at King's College London, which gave rise to the marijuana psychosis link, suggest that skunk users triple their risk of psychosis compared with non-users, and even quintuple it if used daily. According to Amir Englund, one of the proponents of the study, the proportions of THC and CBD are about equal, at 4 percent each, in traditional hash. But in skunk, THC reaches around 14 to 15 percent while there is barely a trace of CBC.
CBD has even shown to be effective as an antipsychotic medicine.
A study in Germany, published in 2013, reportedly found that CBD alleviated psychotic symptoms in 33 patients with schizophrenia without the usual side effects, such as movement disturbances, weight gain and sexual dysfunction. It was shown that in 48 healthy volunteers, 42 percent had psychotic episodes following injections of THC while the number went down to 14 percent when they took a tablet of CBD beforehand. Also, users of CBD were found less likely to suffer paranoid episodes and memory loss onword-recall tests.
Purified cannabidiol was tested by GW Pharmaceuticals in Cambridge, UK as a possible treatment for psychosis in 80 individuals with schizophrenia to see if it reduces their risk of psychosis. Researchers reportedly found that psychosis was three times more likely in those who smoked high-potency skunk compared to non-users.
Robin Murray, who co-led the team at King's College, noted that the risk was fivefold among daily users of skunk. People who smoked low-potency hash were also found to be no more likely to experience psychosis than non-users.
Dr. Marta Di Forti, the lead author of the study, noted that the risk of psychosis in cannabis depends on both the frequency of use and potency. However, the team reportedly discovered that milder variants of cannabis, like hashish, did not increase the risk of psychotic illness.
David Nutt of the Imperial College London, who is for the decriminalization of cannabis, believes that if consumption of cannabis is made legal, the negative effects of the marijuana-psychosis link would be minimized, because skunk would disappear.
http://www.ischoolguide.com/article...ulprit-another-extract-cbd-counters-study.htm